Capricor Therapeutics (NASDAQ:CAPR) CFO Anthony Bergmann Sells 500 Shares

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 500 shares of Capricor Therapeutics stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $30.00, for a total transaction of $15,000.00. Following the completion of the sale, the chief financial officer owned 11,223 shares in the company, valued at $336,690. The trade was a 4.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Anthony Bergmann also recently made the following trade(s):

• On Wednesday, June 24th, Anthony Bergmann sold 400 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $12,000.00.
• On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00.
• On Tuesday, March 31st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.13, for a total value of $753,250.00.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR opened at $29.51 on Thursday. The stock’s 50-day simple moving average is $30.26 and its 200 day simple moving average is $28.40. The company has a market cap of $1.71 billion, a P/E ratio of -12.72 and a beta of 0.39. Capricor Therapeutics, Inc. has a 52-week low of $4.30 and a 52-week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, equities analysts predict that Capricor Therapeutics, Inc. will post -0.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on CAPR shares. Roth Mkm reissued a “buy” rating and issued a $38.00 price objective on shares of Capricor Therapeutics in a report on Friday, May 15th. Piper Sandler restated an “overweight” rating and set a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research report on Friday, March 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $50.30.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CAPR. Creek Drive Management Group LLC acquired a new stake in Capricor Therapeutics during the 4th quarter valued at $1,039,000. Moody Aldrich Partners LLC acquired a new position in shares of Capricor Therapeutics in the fourth quarter valued at $6,025,000. Pier Capital LLC increased its holdings in shares of Capricor Therapeutics by 35.0% in the third quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock valued at $3,580,000 after purchasing an additional 128,837 shares during the last quarter. UBS Group AG raised its position in shares of Capricor Therapeutics by 91.0% in the fourth quarter. UBS Group AG now owns 238,216 shares of the biotechnology company’s stock valued at $6,875,000 after purchasing an additional 113,499 shares during the period. Finally, HBK Sorce Advisory LLC raised its position in shares of Capricor Therapeutics by 19.4% in the fourth quarter. HBK Sorce Advisory LLC now owns 203,705 shares of the biotechnology company’s stock valued at $5,879,000 after purchasing an additional 33,128 shares during the period. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.